These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23675940)

  • 1. Quantitative prediction of glucuronidation in humans using the in vitro- in vivo extrapolation approach.
    Wu B; Dong D; Hu M; Zhang S
    Curr Top Med Chem; 2013; 13(11):1343-52. PubMed ID: 23675940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance.
    Soars MG; Burchell B; Riley RJ
    J Pharmacol Exp Ther; 2002 Apr; 301(1):382-90. PubMed ID: 11907196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
    Gill KL; Houston JB; Galetin A
    Drug Metab Dispos; 2012 Apr; 40(4):825-35. PubMed ID: 22275465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of hepatic and intestinal glucuronidation using in vitro-in vivo extrapolation.
    Naritomi Y; Nakamori F; Furukawa T; Tabata K
    Drug Metab Pharmacokinet; 2015 Feb; 30(1):21-9. PubMed ID: 25760528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical Kinetics and Albumin Effect of Glucuronidation of 5-n-Butyl-4-{4-[2-(1H-tetrazole-5- yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6- dichlorophenyl)-3H-1,2,4-triazol-3-one, a Novel Nonpeptide Angiotensin Type 1 Receptor Antagonist, in Liver Microsomes and UDP-Glucuronosyl-transferase.
    Peng Y; Zhang X; Zhu Y; Wu H; Gu S; Chang Q; Zhou Y; Wang G; Sun J
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29562678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises.
    Miners JO; Knights KM; Houston JB; Mackenzie PI
    Biochem Pharmacol; 2006 May; 71(11):1531-9. PubMed ID: 16455060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uridine 5'-Diphospho-glucuronosyltransferase 1A3 (UGT1A3) Prediction of Hepatic Clearance of Organic Anion Transporting Polypeptide 1B3 (OATP1B3) Substrate Telmisartan by Glucuronidation Using In Vitro-In Vivo Extrapolation (IVIVE).
    Gabor-Worwa E; Kowal-Chwast A; Gaud N; Gogola D; Littlewood P; Smoluch M; Brzózka K; Kus K
    Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):393-403. PubMed ID: 38642299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance.
    Kemp DC; Fan PW; Stevens JC
    Drug Metab Dispos; 2002 Jun; 30(6):694-700. PubMed ID: 12019197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations.
    Mohutsky MA; Chien JY; Ring BJ; Wrighton SA
    Pharm Res; 2006 Apr; 23(4):654-62. PubMed ID: 16550474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance.
    Wattanachai N; Polasek TM; Heath TM; Uchaipichat V; Tassaneeyakul W; Tassaneeyakul W; Miners JO
    Eur J Clin Pharmacol; 2011 Aug; 67(8):815-24. PubMed ID: 21305272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform.
    Ma L; Sun J; Peng Y; Zhang R; Shao F; Hu X; Zhu J; Wang X; Cheng X; Zhu Y; Wan P; Feng D; Wu H; Wang G
    Drug Metab Dispos; 2012 Apr; 40(4):734-41. PubMed ID: 22238289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine.
    Boase S; Miners JO
    Br J Clin Pharmacol; 2002 Nov; 54(5):493-503. PubMed ID: 12445028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of total propofol clearance based on enzyme activities in microsomes from human kidney and liver.
    Al-Jahdari WS; Yamamoto K; Hiraoka H; Nakamura K; Goto F; Horiuchi R
    Eur J Clin Pharmacol; 2006 Jul; 62(7):527-33. PubMed ID: 16763826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data.
    Gill KL; Gertz M; Houston JB; Galetin A
    Drug Metab Dispos; 2013 Apr; 41(4):744-53. PubMed ID: 23303442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward a new paradigm for the efficient in vitro-in vivo extrapolation of metabolic clearance in humans from hepatocyte data.
    Poulin P; Haddad S
    J Pharm Sci; 2013 Sep; 102(9):3239-51. PubMed ID: 23494893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin-Mediated Uptake Improves Human Clearance Prediction for Hepatic Uptake Transporter Substrates Aiding a Mechanistic In Vitro-In Vivo Extrapolation (IVIVE) Strategy in Discovery Research.
    Li N; Badrinarayanan A; Ishida K; Li X; Roberts J; Wang S; Hayashi M; Gupta A
    AAPS J; 2020 Nov; 23(1):1. PubMed ID: 33196949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities.
    Rowland A; Knights KM; Mackenzie PI; Miners JO
    Drug Metab Dispos; 2008 Jun; 36(6):1056-62. PubMed ID: 18362158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats.
    Dalvie D; Kang P; Zientek M; Xiang C; Zhou S; Obach RS
    Chem Res Toxicol; 2008 Dec; 21(12):2260-71. PubMed ID: 19548350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving Prediction of Metabolic Clearance Using Quantitative Extrapolation of Results Obtained From Human Hepatic Micropatterned Cocultures Model and by Considering the Impact of Albumin Binding.
    Da-Silva F; Boulenc X; Vermet H; Compigne P; Gerbal-Chaloin S; Daujat-Chavanieu M; Klieber S; Poulin P
    J Pharm Sci; 2018 Jul; 107(7):1957-1972. PubMed ID: 29524447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans.
    Klieber S; Hugla S; Ngo R; Arabeyre-Fabre C; Meunier V; Sadoun F; Fedeli O; Rival M; Bourrie M; Guillou F; Maurel P; Fabre G
    Drug Metab Dispos; 2008 May; 36(5):851-62. PubMed ID: 18256203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.